Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295975 | 0.81 | KDM4E (0.40) | ATMALDH1A1CA2POLBTYR | |
| SCHEMBL295477 | 0.80 | ALDH1A1 (0.38) | ATMALDH1A1CA2POLBTYR | |
| SCHEMBL8407409 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL2129348 | 0.76 | VCAM1 (0.36) | SMN1; SMN2 | |
| SCHEMBL2126900 | 0.76 | ALDH1A1 (0.35) | ATMALDH1A1CA2POLBTYR | |
| SCHEMBL8094382 | 0.74 | ALDH1A1 (0.45) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL6912228 | 0.74 | VCAM1 (0.49) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL19770698 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL6408936 | 0.73 | VCAM1 (0.36) | SMN1; SMN2 | |
| SCHEMBL28681477 | 0.73 | KMT2A (0.52) | ATMPOLBSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| EP-3230273-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | Cancer Research Technology Ltd (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
| US-8153647-B2 | Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| US-20090203696-A1 | Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1536782-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | disclosed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203696-A1 | Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics | RAB9A, UGT1A9, CD59 | ATM 2533/4885ALDH1A1 1212/4885CA2 4659/4885 |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | ATM 2780/4885ALDH1A1 1788/4885CA2 1579/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | ATM 3432/4885ALDH1A1 1358/4885CA2 314/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | ATM 4585/4885ALDH1A1 3683/4885CA2 180/4885 |
| US-20050065176-A1 | Combinations | CHRNE, CHRND, CHRNG | ATM 3725/4885ALDH1A1 4325/4885CA2 880/4885 |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | PARG, PARP15, PARP12 | ATM 2780/4885ALDH1A1 1788/4885CA2 1579/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | ATM 3432/4885ALDH1A1 1358/4885CA2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.